BACKGROUND AND PURPOSE:The burden of amyloid ␤ is greater in patients with dementia with Lewy bodies than in those with Parkinson disease dementia, and an increased amyloid ␤ load is closely related to a higher incidence of cerebral microbleeds. Here, we investigated the prevalence and topography of cerebral microbleeds in patients with dementia with Lewy bodies and those with Parkinson disease dementia to examine whether cerebral microbleeds are more prevalent in patients with dementia with Lewy bodies than in those with Parkinson disease dementia.

Background: Supradiaphragmatic lymph node metastases (SdLNM) are frequently identified using 18 F-FDG positron emission tomography/computed tomography (PET/CT) in advanced epithelial ovarian cancers (AEOC). This study aimed to determine the prognostic significance of SdLNM detected by PET/CT in patients with AEOC.Methods: Medical records of patients diagnosed with AEOC were retrospectively registered from January 2009 to July 2015. Patients were categorized according to PET/CT stage: PET/CT stage III, PET/CT stage IV with SdLNM, and PET/CT stage IV with other metastases. Clinicopathologic characteristics, recurrence patterns, survival outcomes were compared according to PET/CT stage. Anatomical distribution of SdLNM and effect of thoracic debulking surgery were estimated.Results: A total of 295 patients were identified, including 176 patients who underwent primary debulking surgeries (PDS). Progression-free (P = 0.671) and overall (P = 0.525) survival did not differ significantly between patients with PET/CT IV with SdLNM and PET/CT IV with other metastases; however, patients with PET/CT IV with SdLNM had significantly poorer progression-free (P < 0.001) and overall (P = 0.016) survival than those with PET/CT stage III. Recurrence patterns were similar in all groups; intraperitoneal metastasis was the most common (78.8%) and thoracic recurrence alone accounted for less than 10%. Debulking of SdLNM lesions did not improve progression-free survival (P = 0.425) or overall survival (P = 0.465) of patients with AEOC.Conclusions: SdLNM detected using preoperative PET/CT are a negative prognostic factor in AEOC. Resection of suspicious SdLNM may not have effect to survival of patients with AEOC.

No abstract

No abstract

without metastatic disease, 22 underwent upfront surgery or radiotherapy followed by adjuvant concurrent chemo-radiotherapy (CCRT) or chemotherapy (the local first group); 7 underwent CCRT or chemotherapy before surgery(NAC group); 12 underwent surgery alone, and the remaining 10 underwent CCRT alone. Chemotherapy was administered to 53 (80%) patients. Among the 53 patients, 37 underwent chemo-regimen for small cell carcinoma (CDDP/CBDCA+VP16 or CPT11), whereas the remaining 16 patients underwent chemo-regimen for advanced cervical cancers (weekly CDDP, CDDP+5FU, DTX+CBDCA). The five-year overall survival for all patients was 52%. More specifically, the five-year overall survival by UICC stage I, II, IIIb, and IV was 64%, 76%, 57%, and 0%, respectively. No significant differences in survival were found by FIGO stage (I-IIa vs ! IIb) or by nodal status after excluding patients with UICC stage IV (pZ0.22 and pZ0.49, respectively). Despite the more advanced disease stage, patients in the NAC group tended to have better survival compared to those in the local first group (100% vs 63%; pZ0.12). The five-year survival rates in the small cell carcinoma chemo-regimen group and the advanced cervical cancer chemo-regimen group were 63% and 17%, respectively (P<0.01), and 80% and 33%, respectively (PZ0.07), when limited to CCRT patients. The same trend was observed regardless of UICC stages. Furthermore, no difference in five-year survival was observed between CDDP/CBDCA+VP16 and CDDP+CPT11. Conclusion: SCCC should be treated as localized small cell carcinoma. The application of chemotherapy before surgery may further improve patient survival.